[Reasons for abandonment of hormone replacement therapy with tibolone in menopausal women].
BACKGROUND
Hormone replacement therapy (HRT) with tibolone used in the management of menopause has low rates of acceptance and compliance in the first year. Few studies analyze the reasons for abandoning the use of tibolone.


OBJECTIVE
To analyze the reasons for abandoned tibolone hormone replacement therapy in postmenopausal women and the effects of the drug through the years in the treatment.


METHODS
In a cross-sectional study, were included 261 menopausal women between 40 and 60 year old who attended their disease control at the Gynaecological Endocrinology serving in the National Medical Center Northwest in Obregon City, Sonora, Mexico during 2010-2011. The variables studied included: age, type of menopause, time of use of HRT with tibolone, abandonment reason, development of hypertension, dyslipidemia, hypothyroidism and diabetes mellitus.


RESULTS
A total of 21 women discontinued treatment (8.60%, 95% CI -3 to 19), p=0.0001. The reasons for abandonment included, 42.9% gynecological reasons (23.8% breast disease, 14.3% and 4.8% cervical condition ovarian pathology, p=0.0001). Liver disease and vascular occurred in 28.6%, p=0.050.


CONCLUSIONS
The women studied have adequate adherence to treatment with tibolone (>90%). We don't show an increased risk of cardiovascular or metabolic disease in women studied. Further studies are needed to explore the long-term clinical course, therapeutic response and complications in menopausal patients who use HRT with tibolone.
Hospital General Regional 1 y Hospital de Especialidades 2 de la Unidad Médica de Alta Especialidad, Centro Médico Nacional del Noroeste, Instituto Mexicano del Seguro Social, Ciudad Obregón, Sonora, México.
Francisco Javier
FJ
Zayas-Jaime
Hospital General Regional 1 y Hospital de Especialidades 2 de la Unidad Médica de Alta Especialidad, Centro Médico Nacional del Noroeste, Instituto Mexicano del Seguro Social, Ciudad Obregón, Sonora, México.
José Manuel
JM
Ornelas-Aguirre
Hospital General Regional 1 y Hospital de Especialidades 2 de la Unidad Médica de Alta Especialidad, Centro Médico Nacional del Noroeste, Instituto Mexicano del Seguro Social, Ciudad Obregón, Sonora, México.
Dalia Elizabeth
DE
Pérez-Nápoles
D000328:Adult; D003430:Cross-Sectional Studies; D020847:Estrogen Receptor Modulators / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy / Q000379:methods; D005260:Female; D006801:Humans; D055118:Medication Adherence; D008593:Menopause; D008800:Mexico; D008875:Middle Aged; D009652:Norpregnenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D020847:Estrogen Receptor Modulators; D009652:Norpregnenes; C027385:tibolone